Paul G Auwaerter is the Sherrilyn and Ken Fisher Professor of Medicine at the Johns Hopkins University School of Medicine, serving as the Clinical Director for the Division of Infectious Diseases and Director of the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases.

He serves as the Executive Director of the Johns Hopkins Point of Care-Information Technology (POC-IT) Center producing the Johns Hopkins ABX (Antibiotic), JH HIV, JH Osler, JH Psychiatry and JH Diabetes Guides. Dr. Auwaerter serves as Editor-in-Chief of the ABX Guide. Over the last 20 years, it has become a standard reference for ID-related clinical decision support and rational antimicrobial management. Dr. Auwaerter’s research and clinical interests include improving the diagnosis and care for patients with Lyme disease and other tick-borne infections, surgical infections, Epstein-Barr virus, respiratory diseases, and antibiotic resistance. Dr. Auwaerter has developed therapeutic guidance for COVID-19 in the Johns Hopkins Medical Institutions and facilitated monkeypox care and treatment. He is a Past President of the Infectious Diseases Society of America (IDSA), the largest professional society worldwide related to infectious diseases.

Dr. Katharine Bar is an Associate Professor of Medicine at the University of Pennsylvania within the Division of Infectious Diseases, and Director of the Penn Center for AIDS Research Virus and Reservoirs Core. She is a physician-scientist who studies the basic mechanisms and translational impact of virus transmission, pathogenesis and persistence in HIV, Hepatitis C, and HSV infections. Her lab’s recent work is focused in three related areas: i) understanding mechanisms of HIV persistence and reactivation, ii) developing new antibody-based interventions, and iii) leveraging novel nonhuman primate model systems to test interventions. Clinically, she practices as an Infectious Disease specialist, with a focus on HIV medicine.

Helen Boucher, MD, is the Dean and Professor of Medicine at Tufts University School of Medicine and Chief Academic Officer of the Tufts Medicine Health System. An active Infectious Diseases physician, she was previously Chief of the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and Director of the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance (Levy CIMAR).

Dr. Boucher’s clinical interests include infections in immunocompromised patients and S. aureus Her research interests focus on S. aureus and the development of new anti-infective agents. She is the Chair of the National Institutes of Health Antibacterial Resistance Leadership Group Innovations Working Group and serves on the Executive and Steering Committees. Dr. Boucher has published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and The Annals of Internal Medicine. She is Associate Editor of Antimicrobial Agents and Chemotherapy, and Editor of the Sanford Guide to Antimicrobial Therapy, and Infectious Diseases Clinics of North America.

In 2015, Dr. Boucher was appointed a voting member of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), and elected Treasurer of the Infectious Diseases Society of America (IDSA). She was awarded the IDSA Society Citation Award in October 2015 and the Maxwell Finland Award in 2022. In 2023, she became an Honorary Fellow, Royal College of Physicians of Ireland, the highest award the Royal College of Physicians of Ireland can confer. Dr. Boucher serves as Chair of the Board of Trustees of The College of the Holy Cross and as Chair of the Board of Trustees of the Physicians of Tufts Medical Center.

Dr. Cosgrove is a Professor of Medicine in the Division of Infectious Disease at Johns Hopkins University School of Medicine and has a joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Research for the ID Fellowship Program and PI of the T32 training grant that supports ID fellow training. She serves as the Director of the Department of Antimicrobial Stewardship and an Associate Hospital Epidemiologist at The Johns Hopkins Hospital. Dr. Cosgrove’s research interests include the epidemiology and outcomes of antimicrobial resistance, the development of tools and programs to promote the rational use of antimicrobials, the prevention of hospital-acquired infections, and the epidemiology and management of S. aureus bacteremia.

Early in her career, she recognized the critical need to study antimicrobial stewardship strategies and has led a series of outcomes studies over the past 20 years that have defined the practice of antimicrobial stewardship in the United States. Her recent research focuses on strategies for implementation of antimicrobial stewardship activities across all healthcare settings via a large, multi-center project including hospitals, long-term care facilities and ambulatory practices funded by the Agency for Healthcare Research and Quality, and approaches to improve how antibiotics are given via a randomized trial to compare intravenous and oral therapy for Gram negative bacteremia funded by PCORI. She is the PI of the Johns Hopkins Prevention Epicenter, a Centers for Disease Control and Prevention-funded program that integrates antimicrobial stewardship, healthcare epidemiology, human factors engineering, data science, and implementation science to address knowledge gaps and develop strategies to optimize patient safety by preventing transmission of pathogens and improving antibiotic use in diverse healthcare settings and patient populations. She is a past voting member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria and a Past President of the Society for Healthcare Epidemiology’s Board of Directors. Dr. Cosgrove received her undergraduate degree from Columbia College, her medical degree from Baylor College of Medicine, and her master of science degree in epidemiology from Harvard School of Public Health. She completed her postgraduate training in internal medicine at The Johns Hopkins Hospital and underwent subsequent training in ID at Beth Israel Deaconess Medical Center.

Charles L. Daley, M.D., is Professor of Medicine at National Jewish Health (NJH), the University of Colorado, and Icahn School of Medicine at Mount Sinai. He is Chief of the Division of Mycobacterial and Respiratory Infections and Director of the Nontuberculous Mycobacteria (NTM) Center of Excellence at NJH. Dr. Daley has served on expert panels for the WHO, Centers for Disease Control and Prevention, Infectious Diseases Society of America and American Thoracic Society. In these roles he has served on guideline development committees for diagnosis, treatment and prevention of TB. He chaired the revision of the ATS-led multi-society NTM guideline. He has been recognized as one of the “Best Doctors in America” by U.S. News & World Report and Castle Connolly and he received the World Lung Health Award given by the American Thoracic Society. He was previously Associate Editor of the American Journal of Respiratory and Critical Care Medicine and Associate Editor of The European Respiratory Journal. He is currently Associate Editor of Frontiers in Tuberculosis. His academic interests include clinical and translational research in tuberculosis, NTM infections and bronchiectasis.

Carlos del Rio, MD is a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine and Interim Dean for Emory University School of Medicine. He is also Professor of Global Health and Professor of Epidemiology at the Rollins School of Public Health. He is co-Director of the Emory Center for AIDS Research (CFAR) and co-PI of the Emory Vaccine and Treatment Evaluation Unit. Dr. del Rio’s research focuses on the early diagnosis, access to care, engagement in care, compliance with antiretrovirals and the prevention of HIV infection.  He has worked for over a decade with hard-to-reach populations including substance users to improve outcomes of those infected with HIV and to prevent infection with those at risk. He is also interested in the translation of research findings into practice and policy.    

During the COVID-19 pandemic Dr. del Rio has been a leader locally and nationally, doing research, developing policies, writing scientific publications and making countess media appearances. Dr. del Rio has advised municipal, state, and national leaders including Atlanta Mayor Keisha Lance Bottoms, Tyler Perry Studios, the NCAA, the USTA, Delta Air Lines, Truist Bank, the Atlanta Symphony Orchestra and the Atlanta Opera among others. He also serves on the national advisory committee of the COVID Collaborative, which focuses on developing consensus recommendations and engaging with U.S. leaders on effective policy and coronavirus response. Lastly, Dr. del Rio is an investigator on the Moderna COVID-19 vaccine clinical trial as well as on the ACTT Studies that led to the approval of Remdesivir among other drugs for COVID-19.

Dr. Daniel Diekema is Vice Chair for Research and Director of the Division of Infectious Diseases in the Department of Medicine at Maine Medical Center in Portland, Maine. He is also a Professor Emeritus of Internal Medicine at the University of Iowa, where he served as a director for the Division of Infectious Diseases from 2010-2021. Dr. Diekema received his MD at Vanderbilt University in 1989. He did his residency in internal medicine at the University of Virginia (1989-1992). He did his fellowships in infectious diseases (1992-1995) and medical microbiology (1998-2000) at the University of Iowa. Also while at the University of Iowa, he received his master of science in preventive medicine. As a hospital epidemiologist, infectious diseases clinician and a clinical microbiologist, Dr. Diekema has studied and published extensively on the epidemiology of antimicrobial resistance and health care-associated infections. Dr. Diekema is a past president of the Society for Healthcare Epidemiology of America, and was also a member and co-chair of the CDC Healthcare Infection Control Practices Advisory Committee.

Michael B. Edmond, MD, MPH, MPA, MBA is the Chief Medical Officer of WVU Medicine. In this role he serves as the West Virginia University Health System’s primary physician executive, overseeing clinical services across 25 hospitals and 266 clinics in 4 states with 32,000 employees, 4,000 physicians and advanced practice providers, and annual operating revenue of $6 billion. He also serves as the Chief Medical Officer for the System's two physician practice plans, and Vice Dean for Clinical Affairs at the WVU School of Medicine. Prior to coming to WVU, he was the Chief Quality Officer and Associate Chief Medical Officer at the University of Iowa Hospitals and Clinics, and Professor of Infectious Diseases at the University of Iowa Carver College of Medicine. He also previously served as the Richard P. Wenzel Professor of Internal Medicine, Chair of the Division of Infectious Diseases, and Hospital Epidemiologist at Virginia Commonwealth University in Richmond. 

He is a graduate of the West Virginia University School of Medicine (MD), the University of Pittsburgh School of Public Health (MPH), the Wilder School of Government and Public Affairs at Virginia Commonwealth University (MPA), and the University of Iowa Tippie College of Business (MBA). He was a resident and chief resident in Internal Medicine at West Virginia University Hospitals. He then completed a fellowship in Infectious Diseases at the University of Pittsburgh Medical Center and a fellowship in Hospital Epidemiology at the University of Iowa Hospitals and Clinics. His scholarly focus has been on the epidemiology of healthcare-associated infections and the public policy implications of infection prevention.

Vance Fowler, MD, MHS, Departments of Medicine and Molecular Genetics & Microbiology, Duke University Medical Center. Dr. Fowler is the Florence McAlister Distinguished Professor of Medicine. He has over 2 decades of continuous support as PI from the NIH for clinical and translational research in Staphylococcus aureus and other antibiotic resistant bacterial infections. Dr. Fowler created the S. aureus Bacteremia Group, co-founded the International Collaboration on Endocarditis, and has been the Contact PI of the Antibacterial Resistance Leadership Group since its inception in 2013. He has over 350 peer-reviewed publications with >33,000 citations.

Dr. Goff is an Infectious Diseases Clinical Pharmacist, Professor of Pharmacy Practice and Antibiotic Stewardship Ambassador for The Ohio State University (OSU) Global One Health Institute in Columbus Ohio, USA. She is an awarding winning global “change maker” in infectious diseases. Dr. Goff is one of twenty-five global health experts selected by the World Health Organization (WHO) to implement antibiotic stewardship programs in low middle-income countries. Dr. Goff is the Program Director for the Train the Trainer Antibiotic Stewardship Mentoring Program founded in 2012 with South African pharmacists. Her program continues to expand to include neonatal ASP and other countries including Lebanon and six Latin American countries in collaboration with country experts and neonatal experts at Nationwide Children’s Hospital in Columbus OH. She received the OSU 2019 Distinguished International Outreach and Engagement Award for her global work and the 2017 American College of Clinical Pharmacy Global Health Award. Dr. Goff is the Principal Investigator on the first US study with private practice dentists to assess their antibiotic use and provide guidance on the use of antibiotics in dentistry. Dr. Goff speaks to dental study clubs, dental schools, the FDI World Dental Federation and US Dental CE Academy providing antibiotic stewardship education to over 3,800 dental providers in over 80 countries. Her TEDx talk titled antibiotics “just in case” there’s infection has over 28,500 views on YouTube. She uses X (Twitter) (@idpharmd) to connect with her 10,000 followers. She has 150 publications and 50 grants.

Dr. Andy Hale received his undergraduate education at Middlebury College, then went to medical school at Tufts University School of Medicine. He completed internal medicine residency, chief residency, and infectious diseases fellowship at Beth Israel Deaconess Medical Center. He is now an Infectious Diseases physician and Associate Professor at the University of Vermont Medical Center and an avid medical educator and researcher. He is the course director of cardiac, respiratory, and renal pathophysiology at UVM College of Medicine, Infectious Diseases: past, present, and future at Middlebury College, and Comparative Physiology at Mount Desert Island Biological Laboratory. He is an associate program director for the internal medicine residency at UVMMC.

Hannah Imlay, MD, MS, is an Assistant Professor of Medicine at the University of Utah School of Medicine and the Associate Medical Director of Antimicrobial Stewardship at University of Utah Health and the Salt Lake City Veterans Affairs System. Her clinical and research interests focus on infections and antimicrobial stewardship in immunocompromised hosts, in particular organ transplant recipients and patients undergoing chemotherapy and stem cell transplantation.

Dr. Carl LeBuhn completed medical school, internal medicine residency, chief residency, and infectious diseases fellowship at the University of Iowa. He spent three years on the teaching faculty at the University of Iowa before entering private practice in Paducah, Kentucky in June of 2000. For the past 21 years he has has provided inpatient and outpatient general infectious diseases consultations for western Kentucky and southern Illinois. He has clinical privileges at Baptist Health Paducah, ContinueCare Hospital at Baptist Health Paducah, and Mercy Health Paducah. He and his partner provide HIV/AIDS care to approximately 400 patients through LivWell a federally funded HIV/AIDS organization. He is currently the chair of the Paducah Independent Schools Board of Education and has served on the Board since 2005.

Dr. Marrazzo is the Director of the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health (NIH), where she oversees a $6.3 billion budget that supports research to advance understanding, diagnosis, and treatment of infectious, immunologic, and allergic diseases.  She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021-2023, having served on the board since 2018.

Dr. Marrazzo researches the vaginal microbiome, sexually transmitted infections, and HIV pre-exposure prophylaxis. She has had F roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She has been a leading voice in communicating science during the COVID-19 pandemic.  

Dan Morgan MD, MS is an infectious disease physician and epidemiologist. He is a tenured Professor of Epidemiology and Medicine and Director of the Center for Innovation in Diagnosis at the University of Maryland School of Medicine.  He is Chief of Epidemiology at the VA Maryland Healthcare System. He created testingwisely.com. He Chaired the IDWeek 2022 meeting. He has headlined meetings at the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

His research explores probability in medicine, medical overuse, diagnostic stewardship and infection prevention. He won the NIH New Innovator, SHEA Mid-Career and ACP Alvan Feinstein awards. He has had continuous federal funding and over 200 publications, many in high impact medical journals NEJM, BMJ, JAMA, and JAMA IM.  

Robin Patel is the Elizabeth P. and Robert E. Allen Professor of Individualized Medicine and the Director of the Infectious Diseases Research Laboratory, Co-Director of the Clinical Bacteriology Laboratory, Vice Chair of Education in the Department of Laboratory Medicine and Pathology, and former Chair of the Division of Clinical Microbiology, at the Mayo Clinic.

Since the beginning of her tenure at the Mayo Clinic, Dr. Patel has focused her research on bacterial infections. Her work focuses on three major areas: (1) improvement of next-generation diagnostic techniques, (2) understanding the inherent biology of periprosthetic infection, and (3) understanding antibiotic resistance through a clinical lens. She has published over 595 peer-reviewed publications and is supported by the National Institutes of Health and the Centers for Disease Control and Prevention. She is the Director of the Laboratory Center of the Antibacterial Resistance Leadership Group of the National Institutes of Health.

Dr. Patel received an undergraduate degree in Chemistry from Princeton University, where she graduated magna cum laude. From there, she obtained a medical degree from McGill University. Afterwards, Dr. Patel completed Internal Medicine Residency and Fellowships in Medical Microbiology and Infectious Diseases at the Mayo Clinic. Since then, she has been involved in setting standards for diagnostic and clinical care of bacterial infections, as evidenced by the (select) positions she has held or holds within the American Society for Microbiology (President, Secretary), American Board of Pathology (Microbiology Test Writing Committee Member), Clinical and Laboratory Standards Institute (Subcommittee on Antimicrobial Susceptibility Testing Voting Member), National Institutes of Allergy and Infectious Diseases (Council Member), National Board of Medical Examiners (Microbiology/Immunology Test Material Development Committee Chair), Journal of Clinical Microbiology (Associate Editor), Clinical Infectious Diseases (Associate Editor) and the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (Voting Member).

In addition, Dr. Patel’s continued commitment to mentorship can be translated into a long list of trainees from around the world; she had dedicated hours of teaching to train the next generation of clinical and research laboratory scientists.

More information can be found at: https://journals.asm.org/doi/full/10.1128/JCM.01259-20  

Andrew Pavia M.D. is the George and Esther Gross Presidential Professor and Chief of the Division of Pediatric Infectious Diseases and adjunct Professor of Medicine at the University of Utah. He also serves as Director of Hospital Epidemiology at Primary Children's Medical Center and Associate Director of the Antimicrobial Stewardship Program. He received his MD from Brown University and was a resident and Chief resident in Medicine at Dartmouth. He served as an EIS officer and Preventive Medicine Resident at the Centers for Disease Control and Prevention (CDC) where he worked on diarrheal disease and HIV. He did Pediatric and Adult ID fellowship at the University of Utah.

He is the author of over 200 peer-reviewed papers and 45 invited reviews, editorials and textbook chapters. He currently serves as an advisor to CDC and the Utah Department of Health on COVID-19, and is a member of the NIH COVID-19 Treatment Guidelines Panel. He is a member of the National Academy of Science, Engineering and Medicine’s (formerly known as the IOM) Preparedness Forum. Dr. Pavia co-chairs the Influenza Guidelines Writing Committee for the Infectious Disease Society of America (IDSA), and chaired the IDWeek Program Committee for 2018. He previously served on the Board of Scientific Counselors for CDC, was a board member of IDSA and chair of the IDSA Pandemic Influenza task force and the IDSA Public Health Committee. He has served on the National Vaccine Advisory Committee and the National Biodefense Science Board (NBSB) where he chaired the influenza working group during the 2009 H1N1 influenza pandemic.

He was voted “Utahn of the year” by the Salt Lake Tribune for his efforts to advocate for children during the COVID-19 pandemic and was awarded the “Roz McGee Children’s Champion” award by Voices for Utah Children.  

David A. Relman is the Thomas C. and Joan M. Merigan Professor in Medicine, and a Professor of Microbiology & Immunology at Stanford University, and Chief of Infectious Diseases at the Veterans Affairs Palo Alto Health Care System. He is also Senior Fellow at the Center for International Security and Cooperation at Stanford and served as the Center’s Science Co-Director from 2013-2017. Relman was an early pioneer in the identification of previously unrecognized microbial pathogens, in the development of molecular methods for microbial diagnosis, and in the modern study of the human microbiome (the microbial communities that inhabit the human body). A 2005 paper was one of the first to describe the diversity of the human gut microbiota and has been cited more than 9000 times. His research on the human microbiome has been awarded an NIH Pioneer Award (2006), NIH Transformative Research Award (2013), and the Alexander Fleming Award for Lifetime Achievement from the Infectious Diseases Society of America (2021). He currently examines microbiome stability and resilience using human subjects and experimental clinical perturbation. His group’s work on the vaginal microbiome focuses on understanding the basis for disturbance and recovery following childbirth. He served as President of the Infectious Diseases Society of America, and as Chair of the Forum on Microbial Threats at the US National Academies of Science, and is currently a member of the Defense Science Board for the US Department of Defense and the Science and Security Board of the Bulletin of the Atomic Scientists. He was elected to the National Academy of Medicine in 2011 and the American Academy of Arts & Sciences in 2022.

Dr Ilan Schwartz is an Associate Professor of Medicine and Infectious Diseases physician and researcher at Duke University. His clinical focus is on preventing, diagnosing, and managing infections after transplantation, and his research interest is in invasive fungal infections. More specifically, his research focuses on emerging and endemic fungal pathogens. He serves on the Board of Directors of the Mycoses Study Group Education & Research Consortium and serves on several clinical practice guideline committees. He is an Associate Editor of Clinical Infectious Diseases, and a Deputy Editor of Mycoses.

Dr. Tamma is an Associate Professor of Pediatrics and the Director of the Pediatric Antimicrobial Stewardship Program at The Johns Hopkins University School of Medicine. She is also an Associate Professor in the Department of Epidemiology at The Johns Hopkins Bloomberg School of Public Health. Her research focuses on: (a) elucidating the mechanisms of resistance in gram-negative organisms, (b) developing and enhancing laboratory methods to identify gram-negative resistant organisms to enable critically-ill patients to be placed on appropriate antibiotic therapy as early as possible, and (c) identifying optimal treatment strategies for patients infected with multidrug-resistant gram-negative infections. She is an Editor at Antimicrobial Agents and Chemotherapy, a voting member of the Clinical Laboratory and Standards Institute Antibiotic Susceptibility Testing Subgroup that provides international guidance on establishing antibiotic breakpoints and phenotypic and genotypic methods for identifying antimicrobial resistance, a voting member of the NIH-funded Antibacterial Resistance Leadership Group Gram-Negative Resistance Committee, and the lead author of the Infectious Diseases Society of America Antimicrobial Resistance Treatment Guidance.